The Quantellect read.As of Nov 19, 2026, 3 active firms cover Neurosense Therapeutics Ltd: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $3.00 to $52.00 (about 17.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $23.00 sits 1579% above the current $1.37. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 2 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-3.40 next quarter toward $-4.67 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$23.00
+1578.8% upside
Average target across 3 active firms as of Nov 19, 2026 vs $1.37 current
Highest Target$52.00
Average Target$23.00
Lowest Target$3.00
Detailed analyst forecasts for NRSN
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate NRSN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NRSN EPS & revenue forecast
EPS · THIS QUARTER
$-3.40
Range $-3.40 – $-3.40 · 1 analysts
Next period, 1 analysts expect Neurosense Therapeutics Ltd to earn $-3.40 a share (range $-3.40 – $-3.40), versus — a year earlier. Full-year consensus is $-3.88, growing to $-4.67 the year after.
REVENUE · THIS QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —). Full-year consensus is $0, rising to $2.7M next year.
Top analysts covering Neurosense Therapeutics Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NRSN.
#1
Jason Kolbert
D. Boral Capital · Rank #562
Buy
$14.00+921.9% to target
Overall win rate
22%
+ Follow
#2
NR
Naz Rahman
Maxim Group · Rank #578
Neutral
No targeton NRSN
Overall win rate
27%
+ Follow
#3
James Molloy
Alliance Global Partners · Rank #587
Buy
$150.00+10848.9% to target
Overall win rate
25%
+ Follow
#4
Boobalan Pachaiyappan
Roth Capital
Buy
$60.00+4279.6% to target
Coverage
—
+ Follow
#5
LE
Lander Egaña Gorroño
HC Wainwright & Co.
Buy
$52.00+3695.6% to target
Coverage
—
+ Follow
NRSN stock forecast FAQ
What is NRSN's average 12-month price target?+
The 3 active firms with a live target average $23.00 for Neurosense Therapeutics Ltd over the next 12 months, ranging from a $52.00 high to a $3.00 low, as of Nov 19, 2026.
Is NRSN stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NRSN?+
The Street-high target is $52.00 (HC Wainwright & Co.), and the Street-low is $3.00 (Roth Capital). The average of all 3 active-firm targets is $23.00.
How many active Wall Street firms cover NRSN?+
3 active firms have a recognized rating on Neurosense Therapeutics Ltd as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NRSN?+
Among analysts who currently cover NRSN, Jason Kolbert of D. Boral Capital has the strongest overall Quantellect track record (Rank #562). Their current call is Buy with a $14.00 target.
What is Neurosense Therapeutics Ltd's projected EPS for next quarter?+
The consensus estimate is $-3.40 per share (range $-3.40 – $-3.40) across 1 analysts. Full-year EPS is projected at $-3.88, rising to $-4.67 the following year.
How much revenue is Neurosense Therapeutics Ltd expected to report next quarter?+
Consensus revenue is — (range — – —). Full-year revenue is projected at $0, growing to $2.7M next year.
Have analysts been upgrading or downgrading NRSN lately?+
As of Nov 19, 2026, 3 of 3 active firms rate NRSN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NRSN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.